Psoriasis is a common chronic inflammatory skin disease, presenting in approximately 10% of cases in a severe or complicated form (l). Psoriasis has a well recognised impact on the patient's psychological well-being and quality of life, affecting self-esteem and consequently social relationships (2) (3) . Besides topical treatments and phototherapy, different systemic therapeutic approaches are available for psoriasis, such as cyclosporine (CyA), methotrexate and retinoids such as acitetrin. CyA is widely used to treat moderate to severe conditions that do not respond to first line treatment and in several clinical trials has proved to be effective, with an acceptable tolerability profile, depending on the dose regimen (4) (5) (6) (7) (8) . Different regimens have been employed, varying from short intermittent cycles to a low-dose continuous administration (6) (7) (9) (10) , with percentages ofremission ranging from 76 to 92%.
The present retrospective analysis aims at evaluating, in a historical cohort of patients with severe to moderate psoriasis treated with CyA, which therapeutic regimens are most commonly employed in the clinical practice and the main clinical outcomes in terms of severity of psoriasis and of drug safety obtained with those regimens.
MATERIALS AND METHODS
Three Italian Psoriasis Units participated in the study. Data relative to psonatic patients treated with CyA during the 12 to 36 months preceding the study start were analyzed, provided they were aged 18 years or more and had a diagnosis of moderate to severe psoriasis at the beginning of CyA treatment. Patients with malignancies and other severe chronic diseases or participating in other clinical trials were excluded. The following data were retrospectively collected from the hospital clinical records: patients' demography, history of the disease, evaluation of the disease severity before and after CyA treatment by the Psoriasis Area and Severity Index (PASI) and the physician's judgement, reason for treatment discontinuation and adverse effects.
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The primary objectives of the analysis were the assessment of the evolution of psoriasis severity and the safety of CyA treatment at the regimens employed in common clinical practice. Therapeutic success was defined as complete clearance of lesions, while clinical remission was defined as clearance of psoriatic lesions with residual minor pigmentations. The secondary endpoint is the evaluation of the cost impact ofthe disease for the National Health Service, both in terms of cost of CyA and concomitant therapies and of outpatient visits, hospital admissions, and laboratory examinations for treatment monitoring.
CyA safety was assessed through the review of standard laboratory examinations and of the adverse events registered during the treatment.
For statistical analysis, mean, standard deviation, minimal and maximal values were calculated for quantitative variables, while absolute and relative 
RESULTS
A total of 193 patients were evaluated, with mean age of 45.6 years (range 19-72),59% males, affected with plaque psoriasis (89%), erythroderma (6%), inverse (3%), and pustular (2%) psoriasis. At the time of CyA treatment start, psoriasis was of moderate degree in 18.7% of cases, of moderatesevere degree in 63.7 %, and severe in 17.6 %. Twenty percent of patients had psoriatic arthritis.
CyA was administered for an average period of 14 (SD 12) months, the mean number of treatment courses was 1.6 (range 1-4), the mean dosage ranged from 1.5 (SD 0.6) to 3.1 (SD 0.4) mg/kg/die. Eightythree patients (43%) were treated with CyA in monotherapy. In the other 110 patients, concomitant treatments were administered as follows: combined systemic therapy in 14 subjects, mainly with methotrexate (71%) or retinoids (14%); topical treatments and/or phototherapy in the remaining 96 patients. At the time of data collection, 13% of cases were still on CyA treatment, while the remaining 87% had discontinued treatment due to: achievement of clinical response (56%), completion of scheduled treatment course (29%), poor efficacy (6%), poor tolerability (5%), patient's decision (4%).
The physician's judgement on psoriasis severity before and after CyA treatment is depicted in Fig. 1 . The mean PASI decreased from 23.31 (SD 11.61) before CyA administration to 5.64 (SD 7.41) at the end of treatment. 91.3% of patients evaluated for PASI (n=69) achieved PASI 50 and 73.9% achieved PASI 75. The clinical response to CyA (in monotherapy and with concomitant therapies) is summarized in Table I .
With regard to safety, at least one adverse event occurred in 36% of patients during CyA administration. Type and frequency are reported in Table II . The clinician's judgement on CyA tolerability was good/very good in 90% of cases, poor in 5%, while another 5% of patients had discontinued treatment due to safety issues.
The estimation of the costs borne by the National healthcare system referred to a mean CyA course number of 1.5 and a l4-month observation period. The mean overall per patient cost was 2,984 euros. The direct cost of CyA was 2,058 euros per patient, accounting for 69% of the overall care costs. The remaining costs were 572 euros for hospital admissions, 102 euros for medical visits, 100 euros for laboratory examinations, 105 euros for topical treatments, 26 euros for systemic treatments other than CyA, and 21 euros for phototherapy and rescue treatments.
DISCUSSION
CyAhas been evaluated since the early eighties in open, non-comparative, and even placebo-controlled trials in psoriasis and has shown to be effective in the moderate to severe forms (4) (5) (6) (7) 9) . More than 80% of the treated patients have obtained significant clinical improvements.
The results of this retrospective study first indicate that a low dose CyA regimen was generally employed, starting with 1.5 mglkg/day and not exceeding 3 mglkg/day on average at the last treatment course. Moreover, our analysis confirms that more than 80% of CyA-treated patients obtained a positive clinical response, either complete therapeutic success or disease remission, even with this low dose treatment regimen. CyA treatment was generally well tolerated, with only 5% of patients having discontinued the treatment due to poor tolerability. The side effects profile in our series was quite similar to that reported in literature (11), with hypertension being the most commonly reported adverse event (17.6% of patients). This good tolerability profile allowed long term home treatment with satisfactory clinical outcomes.
The cost analysis revealed that in this series CyA accounts for more than 50% of the overall mean patient cost, followed by hospital admission costs. As a matter of fact, the high rate of efficacy of CyA may justify the higher direct costs for the drug acquisition. On the other hand, CyA is much less expensive than biologics, such as etanercept, infliximab and other newer molecules, which have been more recently introduced in the treatment of severe psoriasis. However, we know that the acquisition costs for the Italian National Health Service vary approximately from 9,000 euros for low dose Enbrel® (25 mg 2 x week) to 14,000 euros for Remicade® (5 mg/kg at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks) for one year of therapy, which is > 4 to 7 times more than the acquisition cost .for CyA in our study.
We are obviously aware that this study suffers from methodological limitations due to its retrospective design and large, prospective, controlled clinical trials should be designed to confirm the low dose efficacy of CyA in moderate to severe psoriasis and address the open issues of the cost-benefit analysis.
